Carla Van Den Berg, Pharm.D.

Articles

1. Van Den Berg, C., McGill, J.R., Kuhn, J.G., Walsh, J.T., De La Cruz, P.S., Davidson, K.K., Wahl, G.M., Von Hoff, D.D. Pharmacokinetics of hydroxyurea in nude mice. Anti-Cancer Drugs 1994; 5: 573-8.
2. Weiss, G.R., Kuhn, J.G., Rizzo, J., Smith, L.S., Rodriguez, G.I., Eckardt, J., Burris, H.A., III, Fields, S., Van Den Berg, K., Von Hoff, D.D. A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid cancers. Cancer Chemother Pharmacol 1994; 35: 397-402.
3. Van Den Berg, C., Guan, X-Y, Von Hoff, D., Jenkins, R., Bittner, M., Griffin, C., Kallonemi, O., Visakorpi, T., McGill J., Hearth, J., Epstein, J., Sarosdy, M., Meltzer, P., Trent, J. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: Potential prognostic implications. Clinical Cancer Res 1994; 1: 11-18.
4. Koeller, J.M., Van Den Berg, C.L. Anemias. In: Yee Young L, Koda-Kimble MA, eds. Applied Therapeutics. 6th ed. Vancouver:Applied Therapeutics; 1995:88-1-17.
5. Van Den Berg, C.L., von Hoff, D.D. “Use of hydroxyurea to alter drug resistance of human tumor cells” In: Mugia FM, ed., Chemotherapy: concepts, mechanisms, and disease targets. Kluwer Academic Publishers; 1995:95-114.
6. Yee, D., Van Den Berg, C., Kozelsky, T.W., Kuhn, J.G., Cox, G.N. Pharmacokinetic profile of recombinant human insulin-like growth factor binding protein-1 in athymic mice. Biomedicine & Pharmacotherapy 1996; 50: 154-157.
7. Van Den Berg, C.L., Kuhn, J.G., Hilsenbeck, S., Cox, G.N., Yee, D. Insulin-like growth factor binding protein-1 (rhIGFBP-1) inhibits growth of breast cancer in athymic mice. Eur Jnl Cancer 1997; 33: 1108-1113.
8. Rocha, R.L., Hilsenbeck, S.G., Jackson, J.G., Van Den Berg, C.L., Weng, C-N, Lee, A.V., Yee, D. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free. Clinical Cancer Research 1997; 3:103-109.
9. Gooch, J.L., Van Den Berg, C.L., Yee, D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death- proliferative and anti-apoptotic effects. Breast Cancer Research and Treatment 1999; 56:1-10.
10. Van Den Berg, C., O’Bryant C. Anemias. In: Yee Young L, Koda-Kimble MA, Young L., eds. Applied Therapeutics: The Clinical Use of Drugs. 7th ed. Philadelphia, Lippincott Williams and Wilkins; 2001:84-1-21.
11. Mamay, C.L., Sion, A.M., Wolf, D.M., Molina, D.M., Van Den Berg, C.L. An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer. Oncogene 2003; 22:602-614.
12. Ferguson, H.A., Marietta, P.M. Van Den Berg, C.L. UV induced apoptosis is mediated independent of caspase-9 in MCF-7 cells- a model for cytochrome C resistance. Journal of Biological Chemistry, 2003; 278:45793-45800.
13. Van Den Berg, C.L. IGF-I influence on breast cancer cell survival. Invited review. Breast Diseases, 2003; 17:49-59.
14. Mingo-Sion, A.M., Marietta, P.M. Koller, E., Van Den Berg, C.L. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation and apoptosis in breast cancer cells. Oncogene 2004; 23:596-604.
15. Mingo-Sion, A.M., Koller, E., Reyland, M.E., Van Den Berg, C.L. mTOR and PKCd interact to regulate stress and ligand mediated phosphorylation of IRS-1 Ser312 in breast cancer cells. Breast Cancer Research and Treatment 2005; 91:259-269.
16. Ferguson, H.A., Marietta, P.M.  Van Den Berg, C.L.  UV induced apoptosis is mediated independent of caspase-9 in MCF-7 cells – a model for cytochrome C resistance.  Journal of Biological Chemistry 2003; 278:45793-45800.
17. Popowski, M., Ferguson, H.A. Mingo-Sion, A.M., Koller, E., Knudsen, E.S., Van Den Berg, C.L… Mammalian target of rapamycin (mTOR) mediates insulin-like growth factor breast cancer survival through retinoblastoma protein.  Journal of Biological Chemistry 2008;283:28265-28273.
18. O’Neal, J.F., Chen, P., Vandenbroek, T.L., Heasley, H.E., Cantrell, M.A., Mitra, S., Van Den Berg, C.L. Jnk2-/- increases tumor development and aneuploidy in the MMTV-Polyoma Middle T Antigen Mammary Tumor Model.  PLoS ONE 2010
19. Mitra, S. Van Den Berg, C.L.  JNK2 enhances cell migration by regulating EPS8 expression, localization, and protein stability in mammary cancer cells. PMID:21357683 Journal of Biological Chemistry 2011;286:15287-15297.
20. Nasrazadani, A., Van Den Berg, C.L. JNK2 Regulates GRB2-associated binding protein 2 (GAB2) to Mediate Mouse Mammary Tumor Growth and Metastasis. Genes & Cancer 2011;2:31-45.
21. Kaoud, T.S., Mitra, S., Lee, S., Taliaferro, J., Cantrell, M., Van Den Berg, C.L., Dalby, K.N. Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration. In Press ACS Chemical Biology 2011;6:658-66.
22. Stone E, Chantranupong L, Gonzalez C, O’Neal J, Rani M, Vandenberg C, Georgiou G. Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy. PMID:22001609 J Control Release. 2012;158:171-9.
23. Ippolito, G.C., Hoi, KH., Reddy, S.T., Carroll, S.M. Tobias Rogosch, T., Chrysostomou, C. Ge, X. Van Den Berg, C.L., Zemlin, M., Shultz, L.D. Ellington, A.D., Georgiou G. Extensive Analysis of the Immunoglobulin Repertoires in humanized NOD-scid-IL2Rgnull mice and Comparison with Human Peripheral Blood B cells. PMID: 22558161 PLoS One. 2012;7(4):e3549.
24. Nancy D. Ebelt, N.D., Cantrell, M., Van Den Berg, C.L. c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade. PMID: 24349635 Genes & Cancer 2013;9-10:378-87.
25. Cantrell, M.A., Ebelt, N.D., Pfefferle, A., Perou, C.M., Van Den Berg, C.L. c-Jun N-terminal Kinase 2 Prevents Luminal Cell Commitment in Normal Mammary Glands and Tumors by Inhibiting p53/Notch1 and Breast Cancer Gene 1 Expression. Oncotarget.In Press
    *Priority Report and Topic of Invited Review
26. Chen, W., Ebelt, N.D., Xhemalce B., Van Den Berg C.L. Miller, K.M. ATM regulation of IL-8 links oxidative stress to cancer cell migration and invasion. eLife In press

---

Abstracts:

1. McGill, J., Meador, R.J., Davidson, K.K., Walsh, J.T., Van Den Berg, C.L., Leal, B.Z., Von Hoff, D.D. Evidence of unstable gene amplification in human ovarian cancer cells. Presented at the 5th Intl. Workshop on Chromosomes in Solid Tumors, Tuscon, AZ, Jan 10-12, 1993.
2. Van Den Berg, C.L., Fields, S.M., Freytes, C.O., LeMaistre, C.F., Koeller, J.M. Clinical outcomes of low-dose granulocyte-colony stimulating factor (G-CSF) in bone marrow transplant (BMT) patients. Proceedings of 4th Intl Symposium Supportive Care in Cancer. OLMA-Messen Conference Centre, St. Gallen, Switzerland, February 24-27, 1993.
3. McGill, J.R., Walsh, J., Durak, M., Van Den Berg, C.L., Segura, L., Von Hoff, D. Unstable gene amplification found in breast cancers taken directly from patients. Proc Am Assoc Cancer Res, 34:129, 1993.
4. Van Den Berg, C.L., McGill, J.R., Von Hoff, D.D. Amplified copies of c-myc occur in both extrachromosomal and intrachromosomal sites of a glioblastoma multiforme cell line. Proc Am Assoc Cancer Res, 34:389, 1993.
5. Van Den Berg, C., McGill, J., Kuhn, J., Walsh, J., De La Cruz, P., Davidson, K., Von Hoff, D. Hydroxyurea pharmacokinetics in nude mice. Proc. Am. Assoc. Cancer Res. 35:428, 1994.
6. McGill, J.R., Mattern, V., Van Den Berg, C.L., Beitzel, B.F., Chang, D., Dai, A. Hodge, J., Eckhardt, S.G. Mapping and characterization of a microdissected colon cancer double minute chromosome. Proc. Am. Assoc. Cancer Res. 36:540, 1995.
7. Van Den Berg, C.L., McDermott, M.J., Stroh, C.A., Reitz, B., Cox, G.N., Yee, D. Insulin-like growth factor binding protein-1 (rhIGFBP-1) inhibits growth of breast cancer in vivo. Breast Cancer Res Treat, 37:104 (Supp),1995.
8. Van Den Berg, C.L., Yee, D. Insulin-like growth factor I (IGF-I) enhances MCF-7 cell growth even in the presence of adriamycin and taxol. Proc Am Assoc Cancer Res 37:220, 1996.
9. Gooch J.L., Van Den Berg, C.L., Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-mediated cell death; proliferative and anti-apoptotic effects. Breast Cancer Research and Treatment 50: 273, 1998.
10. Van Den Berg, C.L., Mamay C., Molina, M. Mechanisms of Insulin-like growth factor-I (IGF-I) chemoprotective effect in MCF-7 breast cancer cells. Breast Cancer Research and Treatment 50: 274, 1998.
11. Van Den Berg, C.L., Mamay C., Molina, M. Mechanisms of Insulin-like growth factor-I (IGF-I) chemoprotective effect in MCF-7 breast cancer cells. Proc Am Assoc Cancer Res 41:406, 2000.
12. Van Den Berg, C.L., Sion, A., Mamay, C.L. Molecular targets for IGF-I protection of irradiated breast cancer cells. Era of Hope. Department of Defense Breast Cancer Research Program Meeting P36-17, 2002.
13. Ferguson, H.A., Marietta, P.M., Van Den Berg, C.L. UV-induced apoptosis occurs independently of the apoptosome in MCF-7 breast cancer cells. Molecular Mechanisms of Apoptosis, Keystone Symposia 2003; 164.
14. Mingo-Sion, A.M. Koller, E., Van Den Berg, C.L. Mammalian target of rapamycin predominantly regulates insulin receptor substrate-1 Ser312 phosphorylation in breast cancer cells. Invited Podium Presentation: Protein Kinases and Cancer: The Promise of Molecular-Based Therapies Keystone Symposia 2004; 216.

Education:

1991 Doctor of Pharmacy, University of Texas Health Science Center at San Antonio & University of Texas-Austin

1989 Bachelor of Science Pharmacy, University of Colorado Boulder, Colorado

Post-doctoral Training:

1991-1992 Clinical Oncology Residency, Audie Murphy VA Hospital, San Antonio, TX. Mentor: Jim Koeller

1992-1994 Oncology Research Fellowship, Cancer Therapy & Research Center, San Antonio, TX. Mentor: Dan von Hoff

1994-1996 Oncology Research Fellowship, University of Texas Health Sciences Center, San Antonio, TX. Mentor: Doug Yee

Academic Appointments:

1990-1991 Graduate Teaching Assistant, University of Texas at Austin, College of Pharmacy

1991-1992 Clinical Pharmacy Resident, Audie Murphy Memorial Hospital and the University of Texas Health Science Center at San Antonio, Texas

1991-1996 Clinical Instructor, Division of Clinical Pharmacy at University of Texas Health Science Center at San Antonio, Texas

1992-1996 Post-doctoral Fellow, Division of Clinical Pharmacy and Division of Oncology, University of Texas Health Science Center at San Antonio, Texas

1996-present Assistant Professor, Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado

1998-present Graduate Faculty, Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, CO

2001-2005 Assistant Professor, School of Pharmacy, Department of Pharmaceutical Sciences (Cross-appointment), University of Colorado Health Sciences Center, Denver, CO

2004-2005 Assistant Professor, School of Medicine, Division of Pharmacology (Cross-Appointment), University of Colorado Health Sciences Center, Denver, CO

July 2005 Associate Professor with tenure, School of Pharmacy, Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, CO

August 2005 Assistant Professor, College of Pharmacy, Division of Pharmacology/Toxicology, University of Texas, Austin

Pharmacy Practice License: Texas # 31302

Colorado # 15161

Pharmacy Practice Experience:

July 1997 to present School of Pharmacy Department: Pharmacy Practice

University of Colorado Health Sciences Ctr. Supervisor: Barry Carter

4200 East Ninth Avenue Courtney Fletcher

Denver, CO Title: Assistant Professor

(303) 315-5229

Apr 2000 to Nov 2000 University of Colorado Hospital Department: Pharmacy

4200 East Ninth Avenue Supervisor: Chris Steckline

Denver, CO Title: FLEX pharmacist

(303) 372-6811

June 1989 to June 1996 San Antonio Regional Hospital Department: Pharmacy

8026 Floyd Curl Drive Supervisor: Debbie Garza

San Antonio, TX Title: Staff Pharmacist

(210) 692-8182

July 1991 to July 1992 Audie Murphy Memorial VA Hospital Department: Pharmacy

7400 Merton Minter Supervisor: Jim Koeller

San Antonio, TX Title: Onc/Hemat. Pharm.D.

(210) 617-5300 ext. 4527 Resident

Feb to June 1991 HEB Grocery Store Department: Pharmacy

15000 San Pedro Supervisor: Michelle Theisen

San Antonio, TX Title: Pharmacist

(210) 494-3203

July 1989 to June 1990 Medical Center Hospital Department: Pharmacy

4502 Medical Drive Supervisor: Yolanda Laurel

San Antonio, TX Title: Staff Pharmacist

(210) 694-2890

Jan 1987 to May 1989 Humana Hospital-Aurora Department: Pharmacy

1501 South Potomac Street Supervisor: Nick Yu

Aurora, CO Preceptor: Nick Yu

(303) 695-2633 Title: Pharmacy Intern

Grant/Research Activity

Grants Pending

None

Grants Funded:

-IGF-I inhibition of doxorubicin activity in breast cancer.- American College of Clinical Pharmacy, July 1997 to June 1998. Principal Investigator, 5% effort. Direct Costs: $10,000.

-Inhibition of chemotherapy activity by growth factor upregulation in breast cancer.- American Association of Colleges of Pharmacy, December 1997 to November 1998. Principal Investigator, 5% effort. Direct Costs: $12,500.

-Mechanisms of chemoresistance in breast cancer by upregulated growth factor pathways.- Susan G. Komen Breast Cancer Foundation, December 1997 to November 1999. Principal Investigator, 25% effort. Direct Costs: $101,343.

-Mechanisms of growth factor attenuation of cell death in chemotherapy treated breast cancer cells.- Department of Defense Cancer Research Program, June 1999 to June 2003. Principal Investigator, approximately 56% effort. Direct Costs: $206,340

-IGF-I Survival effects on p-53 induced apoptosis.- The Charlotte Geyer Foundation, November 2000 to October 2001. Principal Investigator, 25% effort. Direct Costs: $90,909.

-IGF-I survival effects on p53 induced apoptosis.- National Cancer Institute, July 2001 to June 2004. Principal Investigator, 25% effort. Direct Costs: $328,750

-Modulation of Neutrophil Function by cigarette smoke extract.- Philip Morris External Research Program, March 2001 to February 2004. Co-Investigator, 5% effort (Principal Investigator: K. Stringer). Total Budget: $513,593

-P53 dependence of IGF-I survival responses through JNK and Akt.- Avon Breast cancer Foundation Project Grant, November 2000 to October 2001. Principal Investigator, 5% Effort. Direct Costs: $50,000.

-The relationship between melatonin effects on Tumor Necrosis Factor-alpha in older adults with involuntary weight loss.- American Association of Colleges of Pharmacy, December 2000 to November 2001. Co-Investigator, 3% effort (Principal Investigator: R.L. Page). Direct Costs: $10,000.

-The role of JNK in mammary gland development.- University of Colorado Cancer Center Seed Grant, funding period February 2004 to January 2005. Principal Investigator, 3% effort. Direct Costs: $20,000

-Characterization of caspase-9 resistance in breast cancer cells.- Cancer League of Colorado, funding period July 1, 2004 to June 30, 2004. Principal Investigator, 5% effort. Direct Costs: $30,000

-The role of JNK in mammary gland development and tumorigenesis.- National Cancer Institute, December 2004 to November 2009. Principal Investigator, 25% effort. Direct Costs: $1,000,000.

Patent:

SN 08/376,364, Methods of Human Prostate Cancer Diagnosis, John McGill, Carla Van Den Berg, Jeffrey Trent, Daniel Von Hoff and Paul Meltzer.

Publications:

Articles:

1. Van Den Berg, C., McGill, J.R., Kuhn, J.G., Walsh, J.T., De La Cruz, P.S., Davidson, K.K., Wahl, G.M., Von Hoff, D.D. Pharmacokinetics of hydroxyurea in nude mice. Anti-Cancer Drugs 1994; 5: 573-8.

2. Weiss, G.R., Kuhn, J.G., Rizzo, J., Smith, L.S., Rodriguez, G.I., Eckardt, J., Burris, H.A., III, Fields, S., Van Den Berg, K., Von Hoff, D.D. A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid cancers. Cancer Chemother Pharmacol 1994; 35: 397-402.

3. Van Den Berg, C., Guan, X-Y, Von Hoff, D., Jenkins, R., Bittner, M., Griffin, C., Kallonemi, O., Visakorpi, T., McGill J., Hearth, J., Epstein, J., Sarosdy, M., Meltzer, P., Trent, J. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: Potential prognostic implications. Clinical Cancer Res 1994; 1: 11-18.

4. Koeller, J.M., Van Den Berg, C.L. Anemias. In: Yee Young L, Koda-Kimble MA, eds. Applied Therapeutics. 6th ed. Vancouver:Applied Therapeutics; 1995:88-1-17.

5. Van Den Berg, C.L., von Hoff, D.D. “Use of hydroxyurea to alter drug resistance of human tumor cells” In: Mugia FM, ed., Chemotherapy: concepts, mechanisms, and disease targets. Kluwer Academic Publishers; 1995:95-114.

6. Yee, D., Van Den Berg, C., Kozelsky, T.W., Kuhn, J.G., Cox, G.N. Pharmacokinetic profile of recombinant human insulin-like growth factor binding protein-1 in athymic mice. Biomedicine & Pharmacotherapy 1996; 50: 154-157.

7. Van Den Berg, C.L., Kuhn, J.G., Hilsenbeck, S., Cox, G.N., Yee, D. Insulin-like growth factor binding protein-1 (rhIGFBP-1) inhibits growth of breast cancer in athymic mice. Eur Jnl Cancer 1997; 33: 1108-1113.

8. Rocha, R.L., Hilsenbeck, S.G., Jackson, J.G., Van Den Berg, C.L., Weng, C-N, Lee, A.V., Yee, D. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free. Clinical Cancer Research 1997; 3:103-109.

9. Gooch, J.L., Van Den Berg, C.L., Yee, D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death- proliferative and anti-apoptotic effects. Breast Cancer Research and Treatment 1999; 56:1-10.

10. Van Den Berg, C., O-Bryant C. Anemias. In: Yee Young L, Koda-Kimble MA, Young L., eds. Applied Therapeutics: The Clinical Use of Drugs. 7th ed. Philadelphia, Lippincott Williams and Wilkins; 2001:84-1-21.

11. Mamay, C.L., Sion, A.M., Wolf, D.M., Molina, D.M., Van Den Berg, C.L. An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer. Oncogene 2003; 22:602-614.

12. Ferguson, H.A., Marietta, P.M. Van Den Berg, C.L. UV induced apoptosis is mediated independent of caspase-9 in MCF-7 cells – a model for cytochrome C resistance. Journal of Biological Chemistry, 2003; 278:45793-45800.

13. Van Den Berg, C.L. IGF-I influence on breast cancer cell survival. Invited review. Breast Diseases, 2003; 17:49-59.

14. Mingo-Sion, A.M., Marietta, P.M. Koller, E., Van Den Berg, C.L. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation and apoptosis in breast cancer cells. Oncogene 2004; 23:596-604.

15. Mingo-Sion, A.M., Koller, E., Reyland, M.E., Van Den Berg, C.L. mTOR and PKCd interact to regulate stress and ligand mediated phosphorylation of IRS-1 Ser312 in breast cancer cells. Breast Cancer Research and Treatment 2005; 91:259-269.

16. Ferguson, H.A. Mingo-Sion, A.M., Koller, E., Knudsen, E.S., Van Den Berg, C.L… Mammalian Target of Rapamycin mediates Insulin-like Growth Factor breast cancer survival through phosphorylation of Retinoblastoma. In preparation.

Abstracts:

1. McGill, J., Meador, R.J., Davidson, K.K., Walsh, J.T., Van Den Berg, C.L., Leal, B.Z., Von Hoff, D.D. Evidence of unstable gene amplification in human ovarian cancer cells. Presented at the 5th Intl. Workshop on Chromosomes in Solid Tumors, Tuscon, AZ, Jan 10-12, 1993.

2. Van Den Berg, C.L., Fields, S.M., Freytes, C.O., LeMaistre, C.F., Koeller, J.M. Clinical outcomes of low-dose granulocyte-colony stimulating factor (G-CSF) in bone marrow transplant (BMT) patients. Proceedings of 4th Intl Symposium Supportive Care in Cancer. OLMA-Messen Conference Centre, St. Gallen, Switzerland, February 24-27, 1993.

3. McGill, J.R., Walsh, J., Durak, M., Van Den Berg, C.L., Segura, L., Von Hoff, D. Unstable gene amplification found in breast cancers taken directly from patients. Proc Am Assoc Cancer Res, 34:129, 1993.

4. Van Den Berg, C.L., McGill, J.R., Von Hoff, D.D. Amplified copies of c-myc occur in both extrachromosomal and intrachromosomal sites of a glioblastoma multiforme cell line. Proc Am Assoc Cancer Res, 34:389, 1993.

5. Van Den Berg, C., McGill, J., Kuhn, J., Walsh, J., De La Cruz, P., Davidson, K., Von Hoff, D. Hydroxyurea pharmacokinetics in nude mice. Proc. Am. Assoc. Cancer Res. 35:428, 1994.

6. McGill, J.R., Mattern, V., Van Den Berg, C.L., Beitzel, B.F., Chang, D., Dai, A. Hodge, J., Eckhardt, S.G. Mapping and characterization of a microdissected colon cancer double minute chromosome. Proc. Am. Assoc. Cancer Res. 36:540, 1995.

7. Van Den Berg, C.L., McDermott, M.J., Stroh, C.A., Reitz, B., Cox, G.N., Yee, D. Insulin-like growth factor binding protein-1 (rhIGFBP-1) inhibits growth of breast cancer in vivo. Breast Cancer Res Treat, 37:104 (Supp),1995.

8. Van Den Berg, C.L., Yee, D. Insulin-like growth factor I (IGF-I) enhances MCF-7 cell growth even in the presence of adriamycin and taxol. Proc Am Assoc Cancer Res 37:220, 1996.

9. Gooch J.L., Van Den Berg, C.L., Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-mediated cell death; proliferative and anti-apoptotic effects. Breast Cancer Research and Treatment 50: 273, 1998.

10. Van Den Berg, C.L., Mamay C., Molina, M. Mechanisms of Insulin-like growth factor-I (IGF-I) chemoprotective effect in MCF-7 breast cancer cells. Breast Cancer Research and Treatment 50: 274, 1998.

11. Van Den Berg, C.L., Mamay C., Molina, M. Mechanisms of Insulin-like growth factor-I (IGF-I) chemoprotective effect in MCF-7 breast cancer cells. Proc Am Assoc Cancer Res 41:406, 2000.

12. Van Den Berg, C.L., Sion, A., Mamay, C.L. Molecular targets for IGF-I protection of irradiated breast cancer cells. Era of Hope. Department of Defense Breast Cancer Research Program Meeting P36-17, 2002.

13. Ferguson, H.A., Marietta, P.M., Van Den Berg, C.L. UV-induced apoptosis occurs independently of the apoptosome in MCF-7 breast cancer cells. Molecular Mechanisms of Apoptosis, Keystone Symposia 2003; 164.

14. Mingo-Sion, A.M. Koller, E., Van Den Berg, C.L. Mammalian target of rapamycin predominantly regulates insulin receptor substrate-1 Ser312 phosphorylation in breast cancer cells. Invited Podium Presentation: Protein Kinases and Cancer: The Promise of Molecular-Based Therapies Keystone Symposia 2004; 216.

Consulting Activity

1996 to 1998 Alza Pharmaceuticals

2001-2004 U.S. Army Medical Research and Materiel Command/United Information Services: Grant Reviewer for Breast Cancer Research

2002-2003 NIH/NCI: Ad-hoc Reviewer for Metabolic Pathology Study Section

2003 NIH/NCI: Molecular Targets Program Announcement

2003 NIH/Aging Systems and Geriatrics Study Section
Biology of Development and Aging: SBIR/STTR proposals

2003-2004 California Breast Cancer research Program, Pathogenesis Panel

2004-present NIH/NCI: Member of Developmental Therapeutics Study Section

2003 NIH/NCI: Reviewer for Hormone Regulation Cluster Review Panel for Program Projects

Teaching Activity

Pharm.D. Course/Lecture(s)

Track-in Program

Spring, Advanced Pharmacotherapeutics/Kinetics IV, PRDO 5820

1. Treatment of Anemias (2 hrs, from 1997 to 1998)

2. Introduction to Oncology (1 hr, 1999 to 2001)

2. Breast Cancer Pathophysiology and Therapeutics (3 hrs, from 1997 to 2001)

3. Pathophysiology of Viral Infections (2 hours, from 1997 to 2001)

4. HIV/AIDS Therapeutics (2 hours, from 1997 to 1998)

Spring, Professional Skills Development, PRDO 5450, 1998 and 1999

Facilitator for the following skills sessions:

1. Pediatric Medication Administration Issues

2. Physical Assessment of the Pediatric Patient

3. Infectious Disease Case Discussion Sessions

4. AIDS Case Discussion Sessions

5. Cancer Diagnosis and Pathology

6. Treatment of Cancer-related Pain

7. Case Discussions on Anticoagulation

8. Travel Clinic

9. Seizure Disorders
Entry-Level Pharm.D. Program
Spring, Integrated Organ Systems VI, PHRD 4750, 2001 to present
Tumor growth and metastases, clinical staging (2 hrs, 2001 to present)

1. Clinical Approach to the Cancer Patient

2. Pathophysiology of Breast and Prostate Cancer (2 hrs, 2001 to present)

3. Malignancy-induced hypercalcemia (1 hr, 2001 to present)

4. Iron deficiency/Megaloblastic anemias (2hrs, 2001 to present)
Fall, Special Topics in Pharmacokinetics, PRDO 5100

1. Protein Binding of Drugs (2.5 hours, 1997 to 1999)

Bachelor of Science Course/Lecture(s)

Spring, Pharmacotherapeutics II, PHPR 4610

1. Treatment of Viral Infections (2 hrs from 1997 to 2000)

2. Treatment of HIV/AIDS (2 hrs from 1997 to 1998)

Preceptorship/Rotation

Pharm.D. Program

1. Oncology Clinical Rotation (1-2 students per year from 1997 to 1998)

2. Oncology Research Rotation (1-2 students per year from 1997 to 1999)

3. HIV/AIDS Infectious Disease Rotation for Pharmaceutical Care Project (3 students, co-precepted, 1999)

Graduate Program (Toxicology)

1. Research rotations (2 week duration)

2002 4 students (Marta Narvaez, Heather Walczak, Kathryn Zolman, Jessica Krank)
Course Coordination/Course Number

1. Spring 1998 to 1999, Advanced Pharmacotherapeutics/Kinetics, PRDO 5820, 6 credit hours (Co-coordinated)

2. Spring 1999, Advanced Professional Skills Development, PRDO 5450, 3 credit hours (Co-coordinated)

3. Spring 1998, Pathophysiology, PRDO 5600, 3 credit hours, (Co-coordinated)

4. Spring and Fall 2000 to present, Pharm.D. Seminar, PRDO 5480, 1 credit hour

5. Spring 2000-2001, Integrated Organ Systems-6, PHRD 4750, 5 credit hours

Committee Service- to the School of Pharmacy or the Department of Clinical Pharmacy (DOCP)

1. Computer Information Technology Committee, School of Pharmacy (1997)

2. Clerkship Subcommittee, School of Pharmacy (1998)

3. Scientific Foundations Curriculum Focus Group, School of Pharmacy (1998)

4. Scholastic Advancement and Appeals Committee, School of Pharmacy (1998 to present)

5. Research Affairs Committee, American College of Clinical Pharmacy (1998 to present)

6. Advisory Committee, Department of Clinical Pharmacy, School of Pharmacy (1998 to 2001)

7. Search Committee Member for multiple Department of Clinical Pharmacy faculty positions in Oncology (1999 to present (Chair, 2000)), Critical Care (1998), Infectious Disease (1998 and 2001), Pediatrics (1998 to 2000), Geriatrics (2001), HIV (2002, 2003), Tenure-track (2004)

8. Student Remediation Committee (1999)

9. School of Pharmacy Space Committee (2000)

10. Faculty Governance Task Force (2000 to 2001)

11. UCHSC Campus Backfill Committee

12. Professional Service Plan (PSP) Committee (2003)

13. Professional Education DOCP Sub-committee (Chair, 2003)

14. Curriculum Committee (2003 to present)

15. Faculty Senate Officer (2003 to present)

Honors and Awards

Professional Achievement Award, University of Colorado, 1986

American College of Clinical Pharmacy-Cetus Oncology Research Award, 1993

National Cancer Institute T-32 Research Training Grant, 1993 and 1995

Pharmacy Research Award, Post-Doctoral Training Programs, The University of Texas, College of Pharmacy, 1995

American College of Clinical Pharmacy-Rhone-Poulenc Rorer Research Award, 1997

American Association of Colleges of Pharmacy New Investigator Award, 1997

Invited Speaking Engagements:

1. Modulation of Glioma Tumor Behavior by Hydroxyurea. American College of Clinical Pharmacy, St. Louis, MO. August 1994.

2. IGF-I inhibition of doxorubicin induced cell death. Hormones & Cancer Seminar, University of Colorado Cancer Center, Denver, CO. April 1997.

3. Understanding the mechanisms for Insulin-like Growth Factor (IGF)-I Protection of Chemotherapy Treated Breast Cancer Cells. National Grant Conference, Susan G. Komen Foundation, Dallas, TX. October 1998.

4. Mechanisms for Insulin-like Growth Factor Chemoprotection in Breast Cancer Cells. Hormones & Cancer Seminar, University of Colorado Cancer Center, Denver, CO. June 1999.

5. Mechanisms for Insulin-like Growth Factor Chemoprotection in Breast Cancer Cells. 3rd Annual Clinical Pharmacy Oncology Research Conference, Napa Valley, CA. February 1999.

6. Breast cancer cells use stress responses to survive chemotherapy-induced cell death. National Grant Conference, Susan G. Komen Foundation, Dallas, TX. October 1999.

7. Molecular targets for IGF-I protection of chemotherapy treated breast cancer cells. 4th Annual Clinical Pharmacy Oncology Research Conference, St. Thomas, VI. February 1999.

8. IGF-I treatment modulates both stress and survival pathways. Experimental Therapeutics Groups, University of Colorado Cancer Center, Denver, CO. October 2000.

9. The effects of PI 3-kinase dependent kinases in IGF-I signaling responses and breast cancer cell fate. Programs in Hormone-Related Malignancies, University of Colorado Cancer Center, Denver, CO. September 2002

10. The effects of PI 3-kinase dependent kinases in IGF-I signaling responses and breast cancer cell fate. Toxicology Seminar Series, School of Pharmacy, Denver, CO. October 2002.

11. JNK as a therapeutic target for breast cancer treatment. Pharmacology Seminar Series. October 2004.

Professional Activity

Membership in Professional Organizations

American Association of Cancer Research

American Society of Biochemistry and Molecular Biology

University of Colorado Cancer Center

Phi Lambda Sigma, University of Colorado Chapter

Journal Referee

Clinical Cancer Research

Cancer Research

Cancer Chemotherapy and Pharmacology

Oncogene

Journal of Clinical Oncology

Abstract Review
Pharmacy Student Research Conference-Western Region, 1998 to 2000.

Grant Review

Grant Reviewer for University of Colorado Cancer Center Seed Grant and Fellowship Program, 1998 to 2001, 2004.

Grant Reviewer for the U.S. Army Medical Research and Materiel Command Breast Cancer Research Program, 2001-2003 (Genetics Study Panel 2001, 2002; Cell Biology 3 2003)

Ad-hoc grant reviewer for NIH/NCI, Metabolic Pathology Section, February and June 2002

Grant Reviewer for California Breast Cancer Research Program, 2003-2004

Grant Reviewer for NIH/NCI Grant Reviewer for Molecular Targets Program Announcement, June, 2003

Grant Reviewer, NIH/Aging Systems and Geriatrics Study Section
Biology of Development and Aging: SBIR/STTR proposals

Ad-hoc grant reviewer for NIH/NCI, Developmental Therapeutics Section, June 2004

Member of Developmental Therapeutics Section, NIH/NCI study section, Nov 2004 to present

Reviewer for Hormone Regulation Cluster Review Panel for Program Projects June 2005

Committee Service-Graduate Student Thesis Committee

1. Chair (Advisor), Cindy Mamay 1997-2000

2. Member, Nancy Stolpman- 2001 to 2002

3. Member, Patrick Kerzic, 2003-present

4. Member, Ileana Vargas, 2003-present

5. Member, Cathrine Denton 2004-present

Pharm.D. Student Advisor

1. Marty Mattie, Student Advisor and Seminar Advisor (1997)

2. Kristi Townsend for Research Project Presented at the Pharmacy Student Research Conference-Western Region, Estes Park, CO, May 1998.

3. Jim Adams, Julie Kelleher, and Kam Capoccia for the Pharmaceutical Care Project in the HIV Clinic at University Hospital (1998-1999)